In vivo characterization of enTRinsic™ drug delivery technology capsule after intake in fed state: A cross-validation approach using salivary tracer technique in comparison to MRI.


Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
10 11 2019
Historique:
received: 15 07 2019
revised: 19 09 2019
accepted: 12 10 2019
pubmed: 19 10 2019
medline: 9 10 2020
entrez: 19 10 2019
Statut: ppublish

Résumé

The instability of various small molecules, vaccines and peptides in the human stomach is a complex challenge for oral drug delivery. Recently, a novel gastro-resistant capsule - the enTRinsic™ Drug Delivery Technology capsule - has been developed. In this work, the salivary tracer technique based on caffeine has been applied to study the in vivo disintegration of enTRinsic™ capsules in 16 healthy volunteers. In addition, magnetic resonance imaging (MRI) was used to visualize GI transit and to verify the disintegration times determined by using the salivary tracer technique. The enTRinsic™ capsules filled with 50mg of caffeine and 5mg of black iron oxide were administered in the fed state, i.e. 30min after a light meal (500kcal). In the first hour after capsule intake, the subjects were placed in supine position in the MRI scanner and scans were performed in short time intervals. After 1h, the subjects could leave the MRI scanner in between the MRI measurements, which were performed every 15min until disintegration of the capsule was confirmed (maximum observation time: 8h). Saliva samples were obtained simultaneously with MR imaging. Caffeine concentrations in saliva were determined by LC/MS-MS. The starting point of capsule disintegration was determined visually by inspection of the MR images as well as by the onset of salivary caffeine concentrations. In 14 out of 16 subjects, the capsule disintegrated in the small intestine. In one subject, the enTRinsic™ capsule was not emptied from the stomach within the observation time. In another subject, disintegration occurred during gastric emptying in the antropyloric region. In this study, we demonstrated that the enTRinsic™ capsules are also gastro resistant when taken under fed state conditions. Furthermore, we demonstrated the feasibility of using low dose caffeine as a salivary tracer for the determination of the disintegration of an enteric formulation.

Identifiants

pubmed: 31626859
pii: S0168-3659(19)30587-5
doi: 10.1016/j.jconrel.2019.10.023
pii:
doi:

Substances chimiques

Capsules 0
Drug Carriers 0
Caffeine 3G6A5W338E
Ferrosoferric Oxide XM0M87F357

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24-32

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Maximilian Sager (M)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Michael Grimm (M)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Philipp Aude (P)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Philipp Schick (P)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Simon Merdivan (S)

Department of Pharmaceutical Biology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Mahmoud Hasan (M)

Department of Pharmaceutical Chemistry, Future University in Egypt, End of 90th road, Eltagamoa el-Kahmes, New Cairo, Cairo, Egypt; Department of Clinical Pharmacology, University Hospital Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany.

Marie-Luise Kromrey (ML)

Department of Diagnostic Radiology and Neuroradiology, University Hospital Greifswald, Ferdinand-Sauerbruch-Straße, D-17475, Greifswald, Germany.

Aurélien Sivert (A)

Lonza R&D Center of Excellence, Rue Tobias Stimmer - BP 30442, 67412, Illkirch-Graffenstaden, France.

Hassan Benameur (H)

Lonza R&D Center of Excellence, Rue Tobias Stimmer - BP 30442, 67412, Illkirch-Graffenstaden, France.

Mirko Koziolek (M)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany.

Mladen V Tzvetkov (MV)

Department of Clinical Pharmacology, University Hospital Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany.

Werner Weitschies (W)

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, D-17487, Greifswald, Germany. Electronic address: werner.weitschies@uni-greifswald.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH